Search

everythinglearnresearchcommunity

for

Search:↓

Most COVID-19 survivors developed post-acute symptoms, especially if they had been in the ICU, but the severity of initial infection didn't predict these symptoms.

Activating autophagy in dogs with certain diseases improves their skin and hair.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

Loss of TET2 increases the risk of skin and oral cancer.

Valproic acid can cause hair loss, but information on hair color change is not detailed.

Some recovered COVID-19 patients experience skin, hair, and nail issues, suggesting they need follow-up care.

Different methods, including stress management, healthy diet, supplements, and treatments like minoxidil, can help hair grow back after COVID-19 related hair loss.

Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.

COVID-19 diagnosis is linked to new or worsening hair diseases, with stress from the pandemic likely contributing.

Transfer learning with three neural network architectures accurately classifies hair diseases.

Lower 2D:4D ratio and older age increase the risk of severe hair loss in men.

Low PON1 levels may indicate and predict the severity of hair loss.

Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

The PRECISE scale helps estimate how many grafts are needed for hair transplant based on the severity of hair loss.

Iron levels are linked to sleep apnea severity, especially in women with hair loss.

Digital imaging can effectively evaluate the donor area for hair transplants, showing variations in hair density and grouping by age and severity of hair loss.

Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.

Children with autoimmune hair loss have similar vitamin D levels to healthy kids, suggesting no extra screening is needed.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Tofacitinib may help treat severe hair loss, but more research is needed.

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Bimatoprost may help treat hair loss from alopecia areata.

Severe COVID-19 increases the risk of hair loss.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Hypothyroidism is often linked to the hair loss condition telogen effluvium.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.